Loading...
NASDAQ: DBVT
DBV Technologies S.A.
Healthcare · Biotechnology
Market Cap
$465.28M
52w High
$26.19
52w Low
$3.91
P/E
-2.90
Volume
180.35K
Outstanding Shares
23.92M
Company profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
CEODaniel Tassé
SectorHealthcare
IndustryBiotechnology
Employees106
IPO dateOct 22, 2014
Valuation
Forward P/E—
EV/EBITDA-0.31
Enterprise value$34.77M
Stock splits
Nov 29, 20241:5
Jun 7, 20241:2
Profitability & growth
Revenue growth-100%
Gross margin-238.76%
Operating margin-10,164.33%
ROE-415.21%▼700.35%vs FY2023
Analyst consensus
RatingBuy
Target price$46.33▲138.20%
10
Buy
4
Hold
1
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Mar 19, 2026
View
EPS
Actual vs estimate by quarter
Q2'25
ActualEst.
-$0.26
-$0.24
Q3'25
ActualEst.
-$1.55
-$0.21
Q4'25
ActualEst.
-$1.20
-$1.45
Q3FY24
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2'25
ActualEst.
$906.41K
$500K
Q3'25
ActualEst.
$1.74M
$756.53K
Q4'25
ActualEst.
$3.23M
$1.06M
Q3FY24
Next Est.
—